ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (833 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
- First Posted Date
- 2025-10-21
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT07219030
- Locations
- 🇺🇸
ACPRU, Grayslake, Illinois, United States
A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants
- First Posted Date
- 2025-10-21
- Last Posted Date
- 2025-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT07219017
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- Conditions
- Acne Scars
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 395
- Registration Number
- NCT07207369
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
- Conditions
- Solid Tumors Harboring MET Amplification
- Interventions
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 125
- Registration Number
- NCT07196644
A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance
- Conditions
- Mid Face Volume Deficit
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 94
- Registration Number
- NCT07186595
- Prev
- 1
- 2
- 3
- 4
- 5
- 223
- Next
News
Alector's Latozinemab Fails Phase III Trial for Frontotemporal Dementia, Company Cuts Workforce by Half
Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia caused by progranulin gene mutations.
Merck KGaA's Precem-TcT ADC Shows 31% Response Rate in Colorectal Cancer, Advances to Phase III
Merck KGaA's antibody-drug conjugate precemtabart tocentecan (Precem-TcT) demonstrated a 31% objective response rate in heavily pre-treated colorectal cancer patients at 2.8mg/kg dose during Phase I trials.
RINVOQ Demonstrates Superior Efficacy Over HUMIRA in First Head-to-Head Trial for TNF-Inhibitor Experienced Rheumatoid Arthritis Patients
AbbVie's SELECT-SWITCH study marks the first Phase 3b/4 head-to-head trial comparing TNF inhibitor cycling with switching to JAK inhibitor upadacitinib in moderate to severe rheumatoid arthritis patients who failed initial TNF inhibitor therapy.
ADARx Pharmaceuticals to Present Phase 1 Data for ADX-038 siRNA Therapy at ASN Kidney Week 2025
ADARx Pharmaceuticals will present initial Phase 1 clinical data for ADX-038, an investigational siRNA therapy targeting complement factor B, at the American Society of Nephrology Kidney Week meeting in Houston.
Enveric Biosciences Engages IP Firm to Defend Patent Claims Related to AbbVie's $1.2 Billion Bretisilocin Acquisition
Enveric Biosciences has hired Fish and Richardson P.C. to defend its U.S. Patent No. 12,138,276 against a Post-Grant Review petition filed by Gilgamesh Pharmaceuticals.
FDA Approves Expanded RINVOQ Label for IBD Treatment, Allowing Earlier Use When TNF Blockers Inadvisable
The FDA approved an updated indication for RINVOQ (upadacitinib) allowing its use in IBD patients after one systemic therapy when TNF blockers are clinically inadvisable, expanding treatment options beyond the previous requirement for TNF blocker failure.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
AbbVie's ADC Portfolio Shows Promising Results Across Multiple Solid Tumors at ESMO 2025
AbbVie will present new data from its antibody-drug conjugate platform at ESMO 2025, featuring telisotuzumab adizutecan (Temab-A) and ABBV-706 across difficult-to-treat solid tumors.
Eli Lilly and AstraZeneca Emerge as Leading Candidates for Next Trump Administration Drug Pricing Deal
Wall Street analysts predict Eli Lilly and AstraZeneca are the most likely pharmaceutical companies to strike the next drug pricing deal with the Trump administration following Pfizer's September 29 agreement.
AbbVie's BOTOX Shows Promise for Essential Tremor in Phase 2 ELATE Trial
AbbVie's Phase 2 ELATE trial demonstrated that onabotulinumtoxinA (BOTOX) significantly improved tremor disability scores compared to placebo in patients with upper limb essential tremor.